Bio-Path (BPTH) Competitors $0.06 -0.01 (-15.19%) As of 01:09 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFDA EventsHeadlinesOptions ChainSEC FilingsShort InterestTrendsBuy This Stock BPTH vs. GTBP, GLMD, ADTX, LIPO, ATXI, SLRX, CARM, PTIX, CANF, and SPRCShould you be buying Bio-Path stock or one of its competitors? The main competitors of Bio-Path include GT Biopharma (GTBP), Galmed Pharmaceuticals (GLMD), Aditxt (ADTX), Lipella Pharmaceuticals (LIPO), Avenue Therapeutics (ATXI), Salarius Pharmaceuticals (SLRX), Carisma Therapeutics (CARM), Atrinsic (PTIX), Can-Fite BioPharma (CANF), and SciSparc (SPRC). These companies are all part of the "pharmaceutical products" industry. Bio-Path vs. Its Competitors GT Biopharma Galmed Pharmaceuticals Aditxt Lipella Pharmaceuticals Avenue Therapeutics Salarius Pharmaceuticals Carisma Therapeutics Atrinsic Can-Fite BioPharma SciSparc GT Biopharma (NASDAQ:GTBP) and Bio-Path (NASDAQ:BPTH) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, profitability, institutional ownership, risk, earnings, dividends, media sentiment and analyst recommendations. Which has more risk & volatility, GTBP or BPTH? GT Biopharma has a beta of 1.32, meaning that its stock price is 32% more volatile than the S&P 500. Comparatively, Bio-Path has a beta of -0.08, meaning that its stock price is 108% less volatile than the S&P 500. Do analysts recommend GTBP or BPTH? GT Biopharma currently has a consensus target price of $11.00, suggesting a potential upside of 1,490.97%. Given GT Biopharma's stronger consensus rating and higher possible upside, research analysts clearly believe GT Biopharma is more favorable than Bio-Path.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GT Biopharma 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.67Bio-Path 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has higher valuation and earnings, GTBP or BPTH? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGT BiopharmaN/AN/A-$13.16M-$4.07-0.17Bio-PathN/AN/A-$16.08MN/AN/A Do institutionals & insiders hold more shares of GTBP or BPTH? 8.2% of GT Biopharma shares are owned by institutional investors. Comparatively, 5.7% of Bio-Path shares are owned by institutional investors. 3.4% of GT Biopharma shares are owned by insiders. Comparatively, 0.7% of Bio-Path shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Is GTBP or BPTH more profitable? GT Biopharma's return on equity of -1,804.34% beat Bio-Path's return on equity.Company Net Margins Return on Equity Return on Assets GT BiopharmaN/A -1,804.34% -200.12% Bio-Path N/A -2,842.40%-337.48% Does the media favor GTBP or BPTH? In the previous week, GT Biopharma and GT Biopharma both had 1 articles in the media. GT Biopharma's average media sentiment score of 0.93 beat Bio-Path's score of -1.00 indicating that GT Biopharma is being referred to more favorably in the media. Company Overall Sentiment GT Biopharma Positive Bio-Path Negative SummaryGT Biopharma beats Bio-Path on 11 of the 11 factors compared between the two stocks. Get Bio-Path News Delivered to You Automatically Sign up to receive the latest news and ratings for BPTH and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BPTH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BPTH vs. The Competition Export to ExcelMetricBio-PathPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$593K$1.01B$6.09B$10.54BDividend YieldN/A4.84%5.73%4.78%P/E RatioN/A1.2884.6327.10Price / SalesN/A29.97606.05131.34Price / CashN/A17.6437.8662.13Price / Book0.098.0312.246.58Net Income-$16.08M-$7.71M$3.32B$276.75M7 Day PerformanceN/A-0.46%0.76%0.91%1 Month PerformanceN/A26.09%8.03%4.18%1 Year PerformanceN/A-11.66%71.13%35.42% Bio-Path Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BPTHBio-Path0.5858 of 5 stars$0.06-15.2%N/A-93.5%$593KN/A0.0010Negative NewsShort Interest ↑Gap UpGTBPGT Biopharma2.7248 of 5 stars$0.69-6.4%$11.00+1,494.2%-66.1%$2.41MN/A-0.178Gap DownGLMDGalmed Pharmaceuticals2.0049 of 5 stars$1.43-2.7%N/A-61.3%$2.39MN/A-0.0920Short Interest ↓ADTXAditxtN/A$0.47-6.3%N/A-99.8%$2.39M$130K0.0060Short Interest ↑Gap DownLIPOLipella Pharmaceuticals1.0864 of 5 stars$0.51-7.1%N/A-85.5%$2.36M$536.36K-0.134ATXIAvenue Therapeutics2.0985 of 5 stars$0.71-5.1%N/A-65.1%$2.26MN/A0.044News CoverageGap DownSLRXSalarius Pharmaceuticals0.3245 of 5 stars$3.98+0.4%N/A-83.4%$2.01MN/A-0.0920Short Interest ↑CARMCarisma Therapeutics3.1395 of 5 stars$0.05-70.3%$1.93+4,112.3%-95.9%$1.91M$19.63M-0.0320Positive NewsGap UpHigh Trading VolumePTIXAtrinsic0.6385 of 5 stars$3.12-3.9%N/A-61.0%$1.83MN/A-0.332Positive NewsGap DownCANFCan-Fite BioPharma2.3286 of 5 stars$0.51-4.7%$14.50+2,771.3%-79.9%$1.82M$560K-0.298Short Interest ↑SPRCSciSparc0.5755 of 5 stars$3.27-5.9%N/A-15.7%$1.77M$1.31M0.004Gap Down Related Companies and Tools Related Companies GTBP Alternatives GLMD Alternatives ADTX Alternatives LIPO Alternatives ATXI Alternatives SLRX Alternatives CARM Alternatives PTIX Alternatives CANF Alternatives SPRC Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BPTH) was last updated on 10/17/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredGold to $27,533?This week, U.S. gold reserves hit an unprecedented $1 TRILLION in value... And it's sparking urgent chatter...Stansberry Research | SponsoredElon’s Out 🚫. Trump’s DOGE Payouts Keep Flowing (Up to $32K a Year)DOGE payouts are already moving. Every 90 days, billions flow out — whether you’ve claimed your share or not. ...Angel Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bio-Path Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bio-Path With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
